Engineering high affinity, soluble T cell receptors for the treatment of cancer

      Background: T cell receptors (TCRs) bind short peptide fragments derived from endogenously processed proteins that are presented at the cell surface by human leukocyte antigens (HLAs). Natural cancer-specific TCRs have weak affinities for their cognate peptide-HLA (pHLA) complexes, preventing effective T cell mediated tumour clearance. At Immunocore we have developed a new class of bi-specifics, which comprise a soluble, high-affinity TCR targeting a specific cancer-associated pHLA, fused to an anti-CD3 scFv domain. These potent Immune mobilising monoclonal TCRs Against Cancer (ImmTAC) molecules can detect low peptide levels on cancer cells and recruit neighbouring T cells via CD3, leading to the targeted killing of malignant cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to European Journal of Cancer
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect